Skip to main content

Epistem, GSK Partner to Better Understand Fibrosis

NEW YORK (GenomeWeb News) – Epistem today announced a research collaboration with GlaxoSmithKline to use its amplification technology to gain a better understanding of fibrosis.

The Manchester, UK-based firm will use its RNA-Amp technology to identify characteristics of diseased fibrotic tissue, Epistem said. The deal is for three years, but further terms were not disclosed.

Epistem's RNA-Amp technology provides gene expression information from small tissue samples and low number of cells, such as those from cells at the base of a single hair follicle or laser captured microdissected samples, it said.

Last week, Epistem said it had reached a deal with Xcelris Labs of India for the sales and marketing of its rapid molecular tuberculosis diagnostic test.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.